The Pharmacy Times® Oncology Clinical Role section is a comprehensive resource for clinical news and expert insights on issues pertaining to oncology pharmacists.
June 30th 2025
FDA removes REMS for CAR T-cell therapies, enhancing patient access while ensuring safety in cancer treatment.
Chronic IVIG Therapy May Reduce Incidence of Cancer, Especially in Patients With CIDP
June 27th 2025Intravenous immunoglobulin (IVIG) use over an extended period in patients with chronic inflammatory demyelinating polyneuropathy (CIDP) was potentially associated with a reduced incidence of cancer over time, although more research is necessary.
Read More
Jaume Capdevila, MD, PhD, discusses phase 1 data showing promising efficacy and manageable safety for obrixtamig in patients with high DLL3-expressing extrapulmonary neuroendocrine carcinomas, along with ongoing trials evaluating its use in both monotherapy and combination settings.
Read More
OPC 2025: Key Studies Shaping Lung Cancer Therapy From ASCO 2025
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Kevin Chen, PharmD, MS, BCOP, CPP, reviewed several key studies from the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting significant advancements in the treatment of small cell and non–small cell lung cancer.
Read More
OPC 2025: Early and Metastatic GI Cancers See Practice-Changing Trial Results
June 20th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Courtney Cavalieri, PharmD, BCOP, presented clinical trial findings in gastrointestinal (GI) cancers—including colon, gastric, pancreatic, and metastatic colorectal cancer—that highlight the expanding role of immunotherapy and targeted treatments.
Read More
OPC 2025: Advancing Precision Oncology Through Pharmacy-Led Innovation
June 19th 2025At the 2025 Oncology Pharmacists Connect (OPC) meeting, Mya Tran, PharmD, BCOP, highlights the clinical promise, operational challenges, and evolving role of pharmacists in implementing precision medicine and genomics-driven cancer care.
Read More
Midyear Roundup: FDA’s Novel Oncology Drug Approvals in 2025
June 18th 2025In the first half of 2025, the FDA approved 7 novel drugs for oncologic conditions, including for non-small cell lung cancer; ovarian cancer; and metastatic, hormone receptor-positive, human epidermal growth factor 2-negative breast cancer.
Read More
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Read More
Assessing Prescriber Justification for Use of Outpatient Chemotherapy in the Acute Care Setting
This single-center, descriptive, retrospective chart review identified barriers to outpatient chemotherapy use, revealing avoidable inpatient stays and highlighting targets for stewardship interventions.
Read More